Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Position Reduced by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 28.0% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 33,745 shares of the biopharmaceutical company's stock after selling 13,146 shares during the quarter. Wealth Enhancement Advisory Services LLC's holdings in Regeneron Pharmaceuticals were worth $21,403,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Rakuten Securities Inc. boosted its holdings in Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 15 shares during the period. TD Private Client Wealth LLC lifted its position in shares of Regeneron Pharmaceuticals by 9.6% in the 4th quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company's stock worth $122,000 after buying an additional 15 shares during the last quarter. Adirondack Trust Co. boosted its holdings in shares of Regeneron Pharmaceuticals by 4.2% in the 1st quarter. Adirondack Trust Co. now owns 451 shares of the biopharmaceutical company's stock valued at $286,000 after buying an additional 18 shares during the period. Prestige Wealth Management Group LLC grew its position in shares of Regeneron Pharmaceuticals by 23.2% during the 4th quarter. Prestige Wealth Management Group LLC now owns 101 shares of the biopharmaceutical company's stock valued at $72,000 after buying an additional 19 shares during the last quarter. Finally, Ashton Thomas Securities LLC grew its position in shares of Regeneron Pharmaceuticals by 2.5% during the 4th quarter. Ashton Thomas Securities LLC now owns 810 shares of the biopharmaceutical company's stock valued at $577,000 after buying an additional 20 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN traded down $1.98 on Wednesday, reaching $520.29. The company's stock had a trading volume of 639,462 shares, compared to its average volume of 892,854. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.03 and a current ratio of 4.93. The firm's 50 day moving average is $556.44 and its two-hundred day moving average is $637.35. The stock has a market cap of $56.17 billion, a PE ratio of 13.25, a PEG ratio of 1.87 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). The business had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The firm's revenue for the quarter was down 3.7% on a year-over-year basis. During the same period in the prior year, the company earned $9.55 earnings per share. As a group, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.68%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.

Analyst Upgrades and Downgrades

REGN has been the subject of a number of research reports. The Goldman Sachs Group decreased their target price on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. Bank of America dropped their price objective on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating on the stock in a report on Thursday, April 17th. Truist Financial reduced their target price on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. UBS Group decreased their target price on shares of Regeneron Pharmaceuticals from $633.00 to $560.00 and set a "neutral" rating for the company in a research report on Thursday, June 5th. Finally, Canaccord Genuity Group raised Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Tuesday, April 22nd. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $836.48.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.